BioSpace News Archive

INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the world’s only in vivo culture system (IVC), INVOcell®, today announced the Company has received approval by Medical Devices Control Division for FDA Thailand to import and commercialize INVOcell in Thailand.

Sai Life Sciences, a leading global Contract Research, Development & Manufacturing Organization (CRO/ CDMO), today announced that the Japanese regulatory agency, Pharmaceuticals and Medical Devices Agency (PMDA) completed a paper-based compliance inspection of its intermediate & API manufacturing facility in Bidar, India and issued a Certificate of Inspection.

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced seven presentations on amyotrophic lateral sclerosis (ALS) as part of the Motor Neurone Disease Association (MNDA) 32nd International Symposium on ALS/MND, being held virtually December 7-10.

Altamira Therapeutics Ltd. today announced that the first patient has been randomized in its trial for the clinical evaluation of Bentrio (AM-301) in seasonal allergic rhinitis.

Visby Medical, a leading medical diagnostic company, announced results from the cross-sectional single visit patient outcomes and implementation study, which evaluated self-collected vaginal swab samples from 55 women using the Visby Medical Sexual Health Click Test for Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis.

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that The Lancet Psychiatry published results from the Phase 2 ADVANCE study. ADVANCE was an international, 26-week, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of adjunctive pimavanserin treatment.

Since launching in late summer 2021, the innovative Bigfoot Unity™ Diabetes Management Program and its Bigfoot Clinic Hub™ are demonstrating that technology can help transform how health care professionals manage their patient populations on multiple daily injections of insulin.

Philadelphia-based National Disease Research Interchange announces the election of Paul M. Lieberman, Ph.D., to its Board.

BioSig Technologies, Inc. today announced the appointment of Gray Fleming as Chief Commercial Officer.

Cue Health (“Cue”) (Nasdaq: HLTH), a healthcare technology company, today announced it received Pandemic Special Access Route (PSAR) authorization from the Health Sciences Authority (HSA) for the Cue COVID-19 Test for self-testing in Singapore.